FDA holds back on J&J schizophrenia drug

Johnson & Johnson will have to provide the FDA with more information about its candidate schizophrenia drug paliperidone palmitate before it gets approval, the company announced yesterday. J&J's Janssen will market the drug. While J&J did not disclose the specifics of the FDA request, the company did say it will not have to perform any additional studies on the drug and that it intends to comply with FDA and provide the requested information. Release

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.